SLC5A2 and type 2 diabetes mellitus: Dapagliflozin, one such SGLT2 inhibitor, has been approved for clinical therapy of type 2 diabetes, with effects on blood glucose lowering, body weight reduction, and cardiovascular and renal protection [6,7,8].